AbbVie stock gains support from positive QULIPTA trial results
Published on 11/12/2026 at 16:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQULIPTA adds late-stage pipeline support
- AbbVie's Phase 3 TEMPLE study compared QULIPTA with topiramate in adults seeking migraine prevention.
- QULIPTA delivered stronger tolerability and efficacy results across the reported clinical and functional measures.
- Investors will next watch whether the clinical advantage supports prescription growth and commercial execution.
AbbVie reported on October 29, 2026, that its Phase 3 TEMPLE study produced positive results for QULIPTA in migraine prevention. The company said the treatment showed superior tolerability and efficacy compared with topiramate, adding a late-stage clinical data point to its neuroscience pipeline. AbbVie published the results from the head-to-head study.
Lower discontinuation supports positioning
The randomized, double-blind study evaluated atogepant, marketed as QULIPTA, against the highest tolerated dose of topiramate in adults with episodic or chronic migraine. During the 24-week double-blind treatment period, 12% of participants receiving atogepant discontinued treatment because of adverse events, compared with 30% in the topiramate group.
The efficacy results also favored QULIPTA. The treatment met secondary endpoints covering monthly migraine days, headache-related disability, migraine-specific quality of life, patient-reported improvement and cognitive function. The reported findings strengthen AbbVie's competitive argument for an oral preventive option, although the study does not establish the future effect on prescriptions or revenue.
Investors await commercial follow-through
AbbVie stock traded at 267.90 euros on Lang & Schwarz at 16:05 CET on Thursday, November 12, 2026.
AbbVie Inc. stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Lang & Schwarz quote: 267.90 euros at 16:05 CET on November 12, 2026
U.S. equities provide the broader market setting through the S&P 500.
For investors, the next key test is whether QULIPTA's clinical profile translates into sustained prescription growth and a material contribution from AbbVie's migraine franchise. More news and analyses on AbbVie stock.
